Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial
Authors
Alvarez, A. G.Hernando, J.
Jimenez-Valero, G.
Martinez, A.
Fazio, N.
Lopez, C.
Teule, A.
Valle, Juan W
Tafuto, S.
Custodio, A.
Casanovas, O.
Capdevila, J.
Affiliation
Vall d'Hebron University Hospital, Barcelona, SpainIssue Date
2022